More on OTLK
Data
Upcoming Events
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $0.68 |
|
|||
| Open | $0.70 | ||||
| 52 Wk High | $0.03 | ||||
| 52 Wk Low | $0.01 | ||||
| Day High | $0.70 | ||||
| Day Low | $0.65 | ||||
| P/E | N/A | ||||
| EPS | $0.00 | ||||
| Volume | 5,619,639 | ||||
- Form 8-K Outlook Therapeutics, For: Sep 16
- Outlook Therapeutics Fireside Chat from H.C. Wainwright Conference Now Available On-Demand
- Outlook Therapeutics CEO discusses Lytenava FDA approval and U.S. launch
- Outlook Therapeutics CEO, Bob Jahr, Discusses FDA Approval and Commercial Opportunity for LYTENAVA™ in Virtual Investor CEO Connect Segment
- Form 8-K Outlook Therapeutics, For: Aug 23
- Outlook Therapeutics names Kevin Lundquist as CFO ahead of U.S. launch
- Outlook Therapeutics Appoints Kevin Lundquist as Chief Financial Officer as It Prepares for U.S. Commercial Launch of LYTENAVA™
- Outlook Therapeutics CEO, Bob Jahr, Participates in the Virtual Investor “Why Now” On-Demand Conference
- Form SCHEDULE 13G Outlook Therapeutics, Filed by: CVI Investments, Inc.
- Form 10-Q Outlook Therapeutics, For: Jun 30
Entities mentioned with OTLK
- FDA | View Related Stories »
- PDUFA | View Related Stories »
- Maynard Um | View Related Stories »
- Mark Zuckerberg | View Related Stories »
- ARK | View Related Stories »
- H.C. Wainwright | View Related Stories »
- S3 | View Related Stories »
- Earnings | View Related Stories »
- Show More...
